ANZUP 2023 | ANZUP 1301: mitomycin and BCG in non-muscle-invasive bladder cancer

Dickon Hayne, MBBS, MD, FRCS, FRACS, The University of Western Australia, Perth, Australia, provides an overview of the Phase III ANZUP 1301 trial (NCT02948543) of mitomycin to Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer (MIBC). Patients were either randomized to either receive BGC monotherapy or BCG with mitomycin. As a result of current BCG shortages, BCG with mitomycin is an attractive treatment option to maintain BCG stock. This interview took place at the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group annual scientific meeting in Melbourne, Australia.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.